{{Rsnum
|rsid=6877011
|Gene=FLT4
|Chromosome=5
|position=180602471
|Orientation=plus
|GMAF=0.1726
|Gene_s=FLT4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 90.3 | 9.7 | 0.0
| HCB | 31.0 | 38.1 | 31.0
| JPT | 33.3 | 54.8 | 11.9
| YRI | 61.7 | 28.3 | 10.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 31.0 | 38.1 | 31.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=23511629
|Title=VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
|OA=1
}}

{{on chip | HumanOmni1Quad}}